China News Network Guangzhou, June 30 (Cai Minjie) Sun Yat-Sen University Cancer Prevention Center issued the first cancer field treatment prescription in Guangdong on the 30th. Mou Yong, director of the Department of Neurosurgery, said that for many years, the treatment options for glioblastoma have been slow to update, and the treatment of tumor electric field has been confirmed by international large-scale clinical trials to treat glioblastoma effectively and safely.
The patient's family member Mr. Wang (pseudonym) said that at the end of last year, the patient was admitted to the hospital for emergency surgery and was diagnosed as glioblastoma by pathological genetic testing. "Actually, I learned that the electric field treatment of tumors can be used in Hong Kong, but there is no way to go to Hong Kong because of the epidemic situation. Now it can be treated directly in the mainland." Mr. Wang said.
Guangdong issued the first prescription for tumor electric field treatment Zhong Xinshe
Glioblastoma is the tumor with the highest incidence among primary malignant central nervous system tumors, with high malignancy, rapid growth, short course of disease, easy recurrence after operation and high disability, patients with extremely poor clinical prognosis and median survival time Only 15 months, the recurrence rate is close to 100%, and it is considered to be one of the most difficult refractory tumors in neurosurgical treatment.
Mou Yong reported that tumor electric field treatment is a tumor treatment method that uses a specific electric field frequency to interfere with cell division, inhibit tumor growth and cause death of tumor cells affected by the electric field. It can inhibit tumor growth and cause the effect of electric field by interfering with tumor cell mitosis. Cancer cells die. The most common adverse reaction is mild to moderate skin irritation.
On May 13 this year, the State Drug Administration approved tumor electric field therapy for the treatment of newly diagnosed glioblastoma patients in combination with temozolomide, and as a monotherapy for the treatment of patients with recurrent glioblastoma.
International Phase III multi-center clinical study EF-14 confirmed that among newly diagnosed glioblastoma patients, the five-year overall survival rate of patients receiving tumor electric field therapy combined with TMZ treatment was more than doubled compared with temozolomide chemotherapy alone , From 5% to 13%, and the median overall survival time was extended from 16 months to 20.9 months.
Mou Yongcao said that in China, more than 45,000 patients are diagnosed with glioblastoma every year. The market for tumor electric field treatment has broken through the dilemma of domestic glioblastoma treatment for 15 years. "Surgery + radiotherapy and chemotherapy + tumor electric field treatment" has become The new standard treatment plan.
On the same day, the first charity assistance project for glioblastoma patients initiated by the China Primary Health Care Foundation was launched, and Zaiding Pharmaceuticals provided assistance to the China Primary Health Care Foundation for tumor electric field treatment patches, since June 2020 Starting from, eligible low-income patients and low-income patients can apply. (Finish)